Table 4. Frequency of prognostic clinicopathological characteristics of the 58 patients treated with trastuzumab–taxane CT, according to the presence or the absence of T-bet+ cells after CT.

	Presence of T-bet+ cells		Absence of T-bet+ cells
	N	%	N	%	P
Age (years)
<50	14	49	18	62
⩾50	15	51	11	38	0.43
Tumour initial stage
T2	21	72	15	51
T3–T4	8	28	14	49	0.17
Axillary nodal status
Positive	18	62	17	58
Negative	11	38	12	42	0.99
Tumour grade
I+II	19	65	18	62
III	10	35	11	38	0.99
Oestrogen receptor
Positive	18	62	15	51
Negative	11	38	14	49	0.59
Pathological complete response
Yes	15	51	9	31
No	14	49	20	69	0.18

Abbreviation: CT=chemotherapy.